2025
Pilot study evaluating duplex sequencing of urinary DNA as a biomarker for recurrence in non-muscle invasive bladder cancer.
Ghali F, Blaha O, Lam H, Kennedy S, Wright J. Pilot study evaluating duplex sequencing of urinary DNA as a biomarker for recurrence in non-muscle invasive bladder cancer. Journal Of Clinical Oncology 2025, 43: 865-865. DOI: 10.1200/jco.2025.43.5_suppl.865.Peer-Reviewed Original ResearchNon-muscle invasive bladder cancerInvasive bladder cancerVariant allele fractionUrinary DNAIntravesical therapyBladder cancerPathogenic variantsTransurethral resection of bladder tumorMedian time to recurrenceResection of bladder tumorNext-generation sequencingDetection of recurrenceTime to recurrenceTime to relapseRecurrence of tumorBiomarkers of recurrencePilot studyTransurethral resectionBladder tumorsMedian ageRecurrenceAllele fractionUrine samplesTumorBiomarkers
2023
Nature and management of melanoma recurrences following adjuvant anti-PD-1 (PD1) therapy.
Woodford R, McKeown J, Hoeijmakers L, Mangana J, Lebbe C, Zaman F, Aya F, Marsiglio J, Goodman R, Rayson V, Placzke J, Kessels J, Ramelyte E, Haque W, Wilson I, Trojaniello C, Roberts-Thomson R, Robert C, Long G, Menzies A. Nature and management of melanoma recurrences following adjuvant anti-PD-1 (PD1) therapy. Journal Of Clinical Oncology 2023, 41: 9575-9575. DOI: 10.1200/jco.2023.41.16_suppl.9575.Peer-Reviewed Original ResearchDistant recurrenceDefinitive surgeryStage II-IV melanomaManagement of recurrenceTime to recurrenceInternational retrospective studyNovel drug therapiesLR recurrenceResectable recurrencesRecurrent diseaseSystemic therapyAdjuvant therapyMelanoma recurrenceRetrospective studyDrug therapyStage IVClinical trialsRecurrenceStage IIIDisease characteristicsSurgeryTherapyStage IIPD1Patients
2022
Pediatric primary hyperparathyroidism: Surgical pathology and long-term outcomes in sporadic and familial cases
Szabo Yamashita T, Gudmundsdottir H, Foster T, Lyden M, Dy B, Tebben P, McKenzie T. Pediatric primary hyperparathyroidism: Surgical pathology and long-term outcomes in sporadic and familial cases. The American Journal Of Surgery 2022, 225: 699-702. PMID: 36270819, DOI: 10.1016/j.amjsurg.2022.10.018.Peer-Reviewed Original ResearchConceptsPrimary hyperparathyroidismFamilial casesSingle-center retrospective reviewSporadic casesTime to recurrenceSingle gland diseaseRate of recurrenceLong-term outcomesApparent sporadic casesSporadic groupRetrospective reviewSurgical outcomesMEN-1Pediatric patientsGland diseaseFamilial syndromesSurgical pathologyFollow-upGenetic testingPatientsRecurrenceFamily cohortSyndromeMonthsOutcomes
2021
A Multi-institutional Study of Peritoneal Recurrence Following Resection of Low-grade Appendiceal Mucinous Neoplasms
Baumgartner J, Srivastava A, Melnitchouk N, Drage M, Huber A, Gonzalez R, Bell P, Wu E, Resnick M, Turaga K, Poli E, Esquivel J, Deneve J, Kelly K, Veerapong J, Lowy A. A Multi-institutional Study of Peritoneal Recurrence Following Resection of Low-grade Appendiceal Mucinous Neoplasms. Annals Of Surgical Oncology 2021, 28: 4685-4694. PMID: 33415564, DOI: 10.1245/s10434-020-09499-y.Peer-Reviewed Original ResearchConceptsLow-grade appendiceal mucinous neoplasmAppendiceal mucinous neoplasmPeritoneal recurrenceMulti-institutional studyMucinous neoplasmsFollow-upConclusionsThis multi-institutional studyRate of peritoneal recurrenceRisk of peritoneal recurrenceMedian time to recurrenceMulti-institutional retrospective reviewMedian Follow-UpTime to recurrenceSeries of patientsEvidence of perforationExtra-appendiceal mucinFollow-up dataAbsence of perforationAcellular mucinPseudomyxoma peritoneiMedian agePartial cecectomyPrimary endpointRetrospective reviewBackgroundPeritoneal dissemination
2018
BOXIT—A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004)
Kelly J, Tan W, Porta N, Mostafid H, Huddart R, Protheroe A, Bogle R, Blazeby J, Palmer A, Cresswell J, Johnson M, Brough R, Madaan S, Andrews S, Cruickshank C, Burnett S, Maynard L, Hall E, Investigators O. BOXIT—A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004). European Urology 2018, 75: 593-601. PMID: 30279015, DOI: 10.1016/j.eururo.2018.09.020.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, IntravesicalAgedAntibiotics, AntineoplasticAntineoplastic Combined Chemotherapy ProtocolsBCG VaccineCarcinoma, Transitional CellCardiovascular DiseasesCelecoxibCyclooxygenase 2 InhibitorsDisease ProgressionDouble-Blind MethodFemaleHumansMaleMiddle AgedMitomycinNeoplasm Recurrence, LocalNeoplasm StagingQuality of LifeRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeUnited KingdomUrinary Bladder NeoplasmsConceptsNon-muscle-invasive bladder cancerHigh-risk non-muscle-invasive bladder cancerRisk of recurrenceIncreased risk of cardiovascular eventsRisk of cardiovascular eventsTime to recurrenceCardiovascular eventsNMIBC patientsBladder cancerStandard treatmentPhase III placebo-controlled trialIntermediate-risk non-muscle-invasive bladder cancerNon-muscle-invasive bladder cancer patientsIncreased riskPatients treated with celecoxibWeekly mitomycin C instillationsMitomycin C instillationAdjuvant intravesical therapyRecurrence-free rateMedian Follow-UpPlacebo-controlled trialTransitional cell carcinomaHigh-risk patientsCyclo-oxygenase 2 inhibitorsIntravesical therapy
2016
Recurrence and Survival After Resection of Small Intraductal Papillary Mucinous Neoplasm-associated Carcinomas (⩽20-mm Invasive Component)
Winter J, Jiang W, Basturk O, Mino-Kenudson M, Fong Z, Tan W, Lavu H, Vollmer C, Furth E, Haviland D, Klimstra D, Jarnagin W, Lillemoe K, Yeo C, Castillo C, Allen P. Recurrence and Survival After Resection of Small Intraductal Papillary Mucinous Neoplasm-associated Carcinomas (⩽20-mm Invasive Component). Annals Of Surgery 2016, 263: 793-801. PMID: 26135696, PMCID: PMC4957241, DOI: 10.1097/sla.0000000000001319.Peer-Reviewed Original ResearchConceptsIntraductal papillary mucinous neoplasmIPMN-associated carcinomaLymphatic spreadInvasive carcinomaIPMN-associated invasive carcinomaPatterns of invasive diseaseMedian time to recurrencePredictive of poor overall survivalDuct intraductal papillary mucinous neoplasmPredictors of recurrenceSmall invasive cancersTime to recurrenceEarly invasive lesionsIncreasing T stagePredictive of recurrenceHigh-volume centersMulti-institutional experienceEarly invasive carcinomaLymph node metastasisPapillary mucinous neoplasmPoor overall survivalT3 lesionsOverall survivalAdenocarcinoma subtypeSurgical database
2012
Recurrence after microwave ablation of liver malignancies: a single institution experience
Groeschl R, Wong R, Quebbeman E, Tsai S, Turaga K, Pappas S, Christians K, Hohenwalter E, Tutton S, Rilling W, Gamblin T. Recurrence after microwave ablation of liver malignancies: a single institution experience. Hepato Pancreato Biliary 2012, 15: 365-371. PMID: 23458599, PMCID: PMC3633038, DOI: 10.1111/j.1477-2574.2012.00585.x.Peer-Reviewed Original ResearchConceptsRecurrence-free survivalMicrowave ablationLiver tumorsTumor histologyAssociated with time to recurrenceLocal control of liver tumorsMicrowave ablation of liver malignanciesPredictors of early recurrenceRetrospective single-institution reviewLocal controlPrimary tumor histologyMedian tumor sizeSingle-institution reviewPrimary tumor typeMedian Follow-UpTime to recurrenceConcomitant liver resectionPeri-operative morbidityMicrowave ablation proceduresColorectal metastasesMetastatic carcinoidMedian overallConsecutive patientsEarly recurrenceLiver resection
2010
Prognostic factors affecting survival after recurrence in adult living donor liver transplantation for hepatocellular carcinoma
Shin W, Suh K, Lee H, Kim J, Kim T, Yi N, Lee K. Prognostic factors affecting survival after recurrence in adult living donor liver transplantation for hepatocellular carcinoma. Liver Transplantation 2010, 16: 678-684. PMID: 20440777, DOI: 10.1002/lt.22047.Peer-Reviewed Original ResearchConceptsAdult Living Donor Liver TransplantationDonor liver transplantationHepatocellular carcinomaPrognostic factorsLiver transplantationUnresectable diseaseBony metastasesMultiorgan involvementVascular invasionAlpha-fetoprotein level >Multivariate analysisMedian time to recurrenceRecurrent hepatocellular carcinomaTime to recurrenceEarly hepatocellular carcinomaMedian survival timeSurgical resectionRecurrent lesionsGood prognosisShorter survivalAdult patientsUnivariate analysisFollow-upAppropriate treatmentRecurrence
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply